13.26

4.74% 0.60

After Hours: 13.26

Bicara Therapeutics Inc (BCAX)

Overview News Price History Discussions Forecast

Bicara Therapeutics Inc stock is traded at $13.26, with a volume of 502.02K. It is up +4.74% in the last 24 hours and down -0.30% over the past month. Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.

Previous Close:

$12.66

Open:

$12.53

24h Volume:

502.02K

Relative Volume:

1.16

Market Cap:

$722.98M

Revenue:

Net Income/Loss:

P/E Ratio:

EPS:

Net Cash Flow:

1W Performance:

+1.22%

1M Performance:

-0.30%

6M Performance:

-42.84%

1Y Performance:

+0.00%

1-Day Range:

$12.04

$13.71

1-Week Range:

$12.04

$14.39

52-Week Range:

$11.10

$28.09

Bicara Therapeutics Inc Stock (BCAX) Company Profile

Name

Bicara Therapeutics Inc

Sector

Healthcare (1161)

Industry

Biotechnology (676)

Phone

617-785-8308

Address

245 MAIN STREET, CAMBRIDGE

Employee

Twitter

Next Earnings Date

Latest SEC Filings

BCAX's Discussions on Twitter

Compare BCAX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BCAX Bicara Therapeutics Inc	13.26	722.98M	0	0	0	0.00
VRTX Vertex Pharmaceuticals Inc	483.49	124.48B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	625.60	67.45B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	583.62	35.60B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	266.83	34.53B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	274.78	29.15B	3.81B	-644.79M	-669.77M	-6.24

Bicara Therapeutics Inc Stock (BCAX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-06-25	Initiated	Wedbush	Outperform
Dec-06-24	Initiated	H.C. Wainwright	Buy
Nov-05-24	Initiated	Rodman & Renshaw	Buy
Oct-08-24	Initiated	Cantor Fitzgerald	Overweight
Oct-08-24	Initiated	Morgan Stanley	Overweight
Oct-08-24	Initiated	Stifel	Buy
Oct-08-24	Initiated	TD Cowen	Buy

View All

Bicara Therapeutics Inc Stock (BCAX) Latest News

Mar 31, 2025

Cantor Fitzgerald maintains Overweight on Bicara Therapeutics stock - Investing.com

Mar 31, 2025

Promising Data and Durable Responses Drive Buy Rating for Bicara Therapeutics - TipRanks

Mar 31, 2025

Q1 EPS Estimate for Bicara Therapeutics Reduced by Analyst - Defense World

Mar 31, 2025

Mar 29, 2025

Bicara Therapeutics (NASDAQ:BCAX) Earns Outperform Rating from Wedbush - Defense World

Mar 29, 2025

Mar 28, 2025

Charles Schwab Investment Management Inc. Takes Position in Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World

Mar 28, 2025

Stifel raises Bicara stock price target to $48, maintains Buy By Investing.com - Investing.com Canada

Mar 28, 2025

Buy Rating for Bicara Therapeutics Inc. Driven by Promising Clinical Progress and Strong Financial Position - TipRanks

Mar 28, 2025

Bicara Therapeutics Reports Strong Financial Position and Clinical Progress - TipRanks

Mar 28, 2025

Mar 27, 2025

Analysts Adjust Price Targets For Nkarta And Bicara - Evrim Ağacı

Mar 27, 2025

Stifel raises Bicara stock price target to $48, maintains Buy - Investing.com India

Mar 27, 2025

Bank of New York Mellon Corp Makes New Investment in Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World

Mar 27, 2025

Bicara Therapeutics Inc QTRLY Loss Per Share $0.39 - MarketScreener

Mar 27, 2025

Bicara Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - GlobeNewswire

Mar 27, 2025

Bicara Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides ... - Enid News & Eagle

Mar 27, 2025

Mar 26, 2025

Bicara Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2025 - GlobeNewswire

Mar 26, 2025

Mar 18, 2025

Skandinaviska Enskilda Banken AB publ Purchases Shares of 38,035 Bicara Therapeutics Inc. (NASDAQ:BCAX) - MarketBeat

Mar 18, 2025

Mar 15, 2025